HAHabibah Azzahra Putri Agianda

Habibah Azzahra Putri Agianda

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Habibah Azzahra Putri Agianda has a total of 68 co-authors. Here are the top co-authors by number of shared publications:

  • Darius Ebrahimi-Fakhari

    Movement Disorders Program, Department of Neurology Boston Children's Hospital, Harvard Medical School Boston Massachusetts USA

    6 shared publications
  • Joshua Rong

    Movement Disorders Program, Department of Neurology & F.M. Kirby Neurobiology Center Boston Children's Hospital, Harvard Medical School Boston Massachusetts USA

    4 shared publications
  • Kathryn Yang

    Movement Disorders Program, Department of Neurology Boston Children's Hospital, Harvard Medical School Boston Massachusetts USA

    4 shared publications
  • Amy Tam

    Movement Disorders Program, Department of Neurology Boston Children's Hospital, Harvard Medical School Boston Massachusetts USA

    3 shared publications
  • Amy Tam

    Movement Disorders Program, Department of Neurology & F.M. Kirby Neurobiology Center Boston Children's Hospital, Harvard Medical School Boston Massachusetts USA

    3 shared publications
  • Katerina Bernardi

    Movement Disorders Program, Department of Neurology & F.M. Kirby Neurobiology Center Boston Children's Hospital, Harvard Medical School Boston Massachusetts USA

    3 shared publications

Latest Publications

  • KIF1A ‐Associated Neurological Disorder ( KAND ): Spectrum of Movement and Motor Disorders in a Cohort of 51 Patients

    by Katerina Bernardi, Giovana Ribeiro, Nicole Battaglia, Jessica Waxler, Amy Tam, Joshua Rong, Enrique Gonzalez Saez‐Diez, Candace Cameron, Monica Ferrer‐Socorro, Zainab Zaman, et al.

    Background: KIF1A ‐associated neurological disorder (KAND) encompasses a broad neurodevelopmental and neurodegenerative spectrum in which motor and movement disorders are common but incompletely defined. Objectives: To systematically characterize motor and movement disorder phenotypes in KAND. Methods: In this cross‐sectional study, 51 individuals with likely‐pathogenic or pathogenic KIF1A variants underwent standardized neurological assessment using the Spastic Paraplegia Rating Scale (SPRS), SPATAX disability scale, Gross Motor Function Classification System (GMFCS), and Modified Ashworth Scale. Results: A history of global developmental delay was present in 96.1% and neonatal or infantile hypotonia in 62.7%. Progressive spasticity occurred in 72.5%, predominantly affecting the lower extremities and correlated with age ( β = 0.45, odds ratio [OR] = 1.56, 95% confidence intervals [95% CI] 1.09–2.25, P = 0.016). Lower extremity weakness was nearly universal (88.2%) and inversely related with age ( β = −0.08, OR = 0.93, 95% CI 0.86–0.99, P = 0.032). Independent walking was achieved by 62.7% at a median age of 24 months, but only 31.4% retained independent ambulation at last evaluation. Movement disorders included motor stereotypies (43.1%), ataxia (19.6%), action tremor (15.6%), and dystonia (3.9%). Cerebellar signs were present in 37.2%. The p.Glu253Lys variant was associated with the most severe phenotype. Conclusions: KAND encompasses a continuous spectrum of motor and movement disorders that integrates developmental and neurodegenerative features. These findings inform clinical management, genetic counseling, and the design of future clinical trials. © 2026 International Parkinson and Movement Disorder Society.

  • The Movement Disorder Spectrum of ATP1A3 ‐Related Disorders: Cross‐Sectional Analysis and Video Archive of 88 Patients

    by Katerina Bernardi, Anna Zhou, Kathryn Yang, Joshua Rong, Vicente Quiroz, Julian E. Alecu, Habibah A. P. Agianda, Henri J. D. Schmidt, Amy Tam, Siofra Carty, et al.

    Background: ATP1A3 ‐related disorders are characterized by genetic heterogeneity and phenotypic pleiotropy, posing significant challenges for classification. Although canonical phenotypes have traditionally guided decision‐making, increasing evidence highlights their limitations in capturing the clinical complexity. Objective: The aims of this study were to characterize movement disorders, paroxysmal features, and genotype–phenotype relationships; to build a curated video archive; and to assess alignment with canonical phenotypes. Methods: This is an observational study of 88 individuals with pathogenic or likely pathogenic variants in ATP1A3 who were evaluated in specialized movement disorders programs. Results: Age at last clinical follow‐up ranged from 0.1 to 63 years; 80.7% were pediatric patients. Chronic movement disorders were present in 68 of 88 individuals (75%); most had two or more coexisting phenomenologies. Dystonia was most common (47/88, 53%), followed by spasticity (28/88, 32%) and ataxia (28/92, 32%). Paroxysmal events occurred in 78 of 88 (88%) patients, including dystonic spells (45/78, 58%), abnormal eye movements (39/78, 50%), and hemiplegic episodes (37/78, 47%). Common comorbidities included epilepsy (21/88, 24%), cognitive impairment (41/88, 47%), and neuropsychiatric disorders. Only 22 of 88 (25%) fulfilled criteria for a single canonical phenotype; 28 of 88 (32%) met canonical criteria plus additional features, 18 of 88 (20%) satisfied criteria for ≥2 canonical phenotypes, and 20 of 88 (23%) fit no canonical category. We identified 43 distinct ATP1A3 variants; recurrent variants (eg, p.Arg756His, p.Asp801Asn, p.Glu818Lys) showed variable expressivity across categories. Conclusions: The extensive clinical heterogeneity in ATP1A3 ‐related disorders challenges rigid phenotypic classifications. The predominance of patients with overlapping or atypical features supports a shift toward flexible, symptom‐based clinical approaches rather than strict reliance on canonical phenotype recognition. © 2026 International Parkinson and Movement Disorder Society.


  • Longitudinal Dynamics of Plasma Neurofilament Light Chain in Hereditary Spastic Paraplegia Type 11 ( HSP ‐ SPG11 ) and Type 15 ( HSP ‐ ZFYVE26 )

    by Habibah A.P. Agianda, Julian E. Alecu, Amy Tam, Hyo‐Min Kim, Joshua Rong, Nicole Battaglia, Kaitlyn Warren, Rebekah Mannix, Nunzio Setola, Melissa Barghigiani, et al.

    Background: HSP‐ SPG11 and HSP‐ ZFYVE26 are autosomal‐recessive forms of hereditary spastic paraplegias (HSPs). As therapeutic trials emerge, validated biomarkers are critically needed. Objectives: To evaluate plasma neurofilament light chain (pNfL) as a biomarker for neurodegeneration and disease progression. Methods: We analyzed pNfL levels in 57 patients (36 HSP‐ SPG11 , 21 HSP‐ ZFYVE26 ) and matched controls using single‐molecule array technology. Longitudinal clinical and biomarker data were collected over 5 years. Results: Baseline pNfL levels were significantly elevated in patients: 33.85 pg/mL (IQR 25.15–47.38) in HSP‐ SPG11 , 46.70 pg/mL (IQR 29.95–54.84) in HSP‐ ZFYVE26 , and 4.90 pg/mL (IQR 3.48–6.90) in controls ( P < 0.001). No significant difference was observed between HSP‐ SPG11 and HSP‐ ZFYVE26 . In matched pair analysis, pNfL showed inverse correlation with age (ρ = −0.463, P < 0.001). Baseline pNfL did not predict future clinical progression. Conclusions: Elevated pNfL reflects early neuroaxonal injury in HSP‐ SPG11 and HSP‐ ZFYVE26 ; however, it could not be used as a surrogate for disease progression. © 2025 International Parkinson and Movement Disorder Society.


  • Spectrum of Movement Disorders in Early‐Onset Hereditary Spastic Paraplegia: A Study of 428 Cases

    by Dario Resch, Julian E. Alecu, Kathryn Yang, Vicente Quiroz, Luca Schierbaum, Katerina Bernardi, Zainab Zaman, Habibah A.P. Agianda, Joshua Rong, Nicole Battaglia, et al.

    Background: Movement disorders occur in early‐onset hereditary spastic paraplegia (HSP), but their prevalence, genotype associations, and clinical impact are not well defined. Objectives: To delineate the spectrum and frequency of movement disorders across childhood‐onset HSP genotypes and assess associations with clinician‐ and caregiver‐reported outcomes. Methods: We performed a cross‐sectional analysis of 428 children and young adults with molecularly confirmed HSP enrolled in a multicenter natural history study. Standardized clinical phenotyping and video examinations were reviewed. Movement and motor disorders (dystonia, ataxia, parkinsonism, tremor, choreoathetosis) were identified using predefined criteria. Associations with SPATAX‐EUROSPA disability stage (SPATAX), Spastic Paraplegia Rating Scale (SPRS; total and spasticity subscore), Modified Ashworth Scale, and Caregiver Priorities and Child Health Index of Life with Disabilities (CPCHILD) quality‐of‐life scores were analyzed with nonparametric tests and multivariable linear models adjusted for age and sex. Results: Movement disorders were present in 27.6% (118/428) of participants; 22.8% of these had ≥2 movement disorders. Dystonia (16.4%) and ataxia (10.0%) predominated. Distinct genotype‐specific patterns were observed: dystonia in SPG4, SPG3A, and AP‐4‐HSP; parkinsonism in SPG11; and ataxia in SPG15, SPG76, SPG7, SPG5a, and SPG46. Presence of any movement disorder correlated with greater disability and motor burden and lower quality of life. In adjusted models, dystonia and parkinsonism were associated with higher SPATAX and SPRS scores, whereas ataxia and tremor correlated with lower scores; dystonia showed the largest decrement in CPCHILD. Conclusions: Movement disorders are common, genotype‐specific, and clinically impactful features of childhood‐onset HSP. Routine screening and genotype‐tailored management of movement disorders, especially dystonia, may improve functional outcomes and quality of life. © 2025 International Parkinson and Movement Disorder Society.


  • DBSMatchMaker: Connecting Clinicians Globally for Deep Brain Stimulation in Rare Diseases

    by Umar Zubair, Habibah A.P. Agianda, Kathryn Yang, Amy Tam, Joshua Rong, Carolina Gorodetsky, Shekeeb S. Mohammad, Juan Darío Ortigoza‐Escobar, Darius Ebrahimi‐Fakhari


  • Open Access

    Dent Disease 1 Presented Early with Bartter-Like Syndrome Features and Rickets: A Case Report

    by Cahyani Gita Ambarsari, Habibah Azzahra Putri Agianda, Meilania Saraswati, Jon Jin Kim

    Introduction: Dent disease (DD) is characterized by a triad of low-molecular-weight proteinuria, hypercalciuria, and nephrocalcinosis/nephrolithiasis. However, some cases were confounded by other clinical symptoms and signs, namely, hypokalemia and rickets, which resulted in misleading diagnoses. A diagnosis of DD could be delayed even in high-resource countries due to its variability of phenotypes and rarity, causing a lack of awareness in both medical practitioners and parents. Moreover, in low-resource countries, laboratory test limitations can hinder the diagnosis. Case Presentation: A thirteen-year-old boy presented with an acute episode of severe hypokalemia following vomiting due to COVID medication side effects. He had lower extremities weakness, salt craving, and polydipsia since childhood which were not thought to be unusual by the parents. He had a history of intrauterine polyhydramnios and maternal miscarriages. A physical examination showed hypotension, short stature, and genu valgum. His laboratory workup displayed hypokalemic metabolic alkalosis and increased urine potassium, chloride, transtubular potassium gradient, and calcium/creatinine ratio. He also had hypophosphatemia, hypomagnesemia, and decreased kidney function. Severe osteopenia was prominent on radiologic examination of all extremities. Subsequent laboratory samples sent overseas revealed low-molecular-weight proteinuria and a pathogenic variant in the CLCN5 gene confirming X-linked DD 1. Conclusion: This case report highlights the importance of considering DD in differential diagnoses of children with the pseudo-Bartter syndrome, that is, renal salt and potassium wasting, with or without hypercalciuria and nephrocalcinosis. Additionally, in children with rickets and proteinuria, urinary low-molecular-weight protein measurement could assist in screening for the possibility of DD, particularly in low-resource settings.


  • STUB1‐Associated Autosomal‐Recessive Spinocerebellar Ataxia Type 16 (SCAR16) Presenting with Gordon–Holmes Syndrome Caused by Maternal Uniparental Isodisomy

    by Habibah A.P. Agianda, Amy Tam, Avaneesh Kunta, Umar Zubair, Afshin Saffari, Joshua Rong, Michelle Crough, Rasha Srouji, Vicente Quiroz, Kathryn Yang, et al.